What is the 13F Pro Quality Score for DNTH?

13F Pro ranks Dianthus Therapeutics, Inc. /DE/ (DNTH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DNTH's current score at https://13fpro.ai/research/DNTH (free sign-up required for the full ranking).

Which hedge funds own the most DNTH stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of DNTH include FMR, BlackRock,, RA CAPITAL MANAGEMENT, L.P.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/DNTH as soon as new 13F filings post.

Where does 13F Pro source DNTH data?

All Dianthus Therapeutics, Inc. /DE/ fundamentals and ownership data come directly from SEC EDGAR. Dianthus Therapeutics, Inc. /DE/ files with the SEC under CIK 1690585. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DNTH in?

Dianthus Therapeutics, Inc. /DE/ (DNTH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is DNTH research updated on 13F Pro?

DNTH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Dianthus Therapeutics, Inc. /DE/(DNTH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1690585 DNTH stock profile & AI dashboard →

13F Pro Quality Score

26.8/100

Rank #2,490 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

30.0/100

Profitability

30.0/100

Balance Sheet

8.8/100

Earnings Quality

30.0/100

Free Cash Flow

30.0/100

Institutional Flow

59.4/100

Revenue Scale

30.0/100

Dilution Risk

0.7/100

DNTH Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Dianthus Therapeutics, Inc. /DE/ (DNTH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DNTH at 26.8/100 on a 32-signal composite quality model, placing it at rank #2,490 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (8.8) and revenue growth (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Dianthus Therapeutics, Inc. /DE/ reports net income of $-40.8M, free cash flow of $-28.9M. Top institutional holders of DNTH by reported 13-F value include FMR, BlackRock,, RA CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. DNTH trades on the Nasdaq exchange and files with the SEC under CIK 1690585. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DNTH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Dianthus Therapeutics, Inc. /DE/ directly from SEC EDGAR. Dianthus Therapeutics, Inc. /DE/'s 13F Pro composite quality score has ranged between 6 and 27 since 2024, currently 26.8 — a stable long-term trajectory across 15 quarterly and live scoring snapshots.

✦

Fun facts about Dianthus Therapeutics, Inc. /DE/

Quirks, history, and lore behind DNTH — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in New York · focused on serious inflammatory and autoimmune diseases.
2
The Numbers
Like most clinical-stage biotechs, it has no product revenue yet — it runs on cash reserves and has a relatively small headcount, typical of a pre-commercial biotech.
3
The History
The company was spun out of Verseon — wait, no — it was formed out of assets and talent from Anokion and relaunched as an independent public company in the early 2020s.
4
The Secret
Its lead therapeutic approach zeroes in on BAFF and APRIL — two proteins that keep disease-causing B cells alive longer than they should be.
5
The Lore
Its lead drug candidate targets IgA nephropathy — a kidney disease caused by rogue antibodies — using a bispecific antibody designed to cut off the fuel supply to misbehaving immune cells.
6
The Giveaway
Named after a genus of flowering carnation plants, this biotech's ticker is DNTH and its lead asset DNTH103 is gunning to make a name in complement-driven kidney disease.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q1 2026

$-40.8M

Free Cash Flow

Q1 2026

$-28.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+91.5% YoY

$2.8MFY 2023

FY18 $0.00FY19 $0.00FY21 $1.5MFY23 $2.8M

Net Income

+38.8% YoY

$-43.5MFY 2023

FY18 $-57.5MFY19 $-76.8MFY21 $-71.1MFY23 $-43.5M

Operating Income

+35.5% YoY

$-48.2MFY 2023

FY18 $-60.0MFY19 $-83.0MFY21 $-74.7MFY23 $-48.2M

EPS (Diluted)

-555.0% YoY

$-8.45FY 2023

FY18 —FY19 —FY21 $-1.29FY23 $-8.45

Total Assets

-5.5% YoY

$179.4MFY 2023

FY18 $157.3MFY19 $161.5MFY21 $189.9MFY23 $179.4M

Op. Cash Flow

+38.1% YoY

$-36.9MFY 2023

FY18 $-41.9MFY19 $-57.1MFY21 $-59.5MFY23 $-36.9M

Metric	FY 2023	FY 2021	FY 2019	FY 2018	FY 2016	FY 2015
Revenue	$2.8M +91.5%	$1.5M	$0.00	$0.00	$0.00	—
Net Income	$-43.5M +38.8%	$-71.1M +7.4%	$-76.8M -33.5%	$-57.5M -509.7%	$-9.4M	—
Operating Income	$-48.2M +35.5%	$-74.7M +10.0%	$-83.0M -38.4%	$-60.0M -547.0%	$-9.3M	—
EPS (Diluted)	$-8.45 -555.0%	$-1.29	—	—	—	—
Total Assets	$179.4M -5.5%	$189.9M +17.6%	$161.5M +2.7%	$157.3M	—	—
Operating Cash Flow	$-36.9M +38.1%	$-59.5M -4.3%	$-57.1M -36.3%	$-41.9M -541.5%	$-6.5M	—

AI Insight: DNTH Financial Trends

Dianthus shows accelerating cash burn with operating cash flow losses widening from $15M in Q2 2024 to $29M in Q1 2026 despite a major equity raise.

• Operating cash flow losses worsened from $15M in Q2 2024 to $29M in Q1 2026.

• Equity jumped from $493M in Q4 2025 to $1,201M in Q1 2026, indicating substantial capital raise.

• Net losses deepened from $18M in Q2 2024 to $41M in Q1 2026.

• Revenue remains minimal with only $1M recorded in Q1 2025, then zero thereafter.

⚠ Q4 2025 showed exceptional $64M net loss spike before moderating to $41M in Q1 2026.

⚠ Burn rate sustainability given current equity base of $1.2B versus quarterly cash outflows near $30M.

AI Insight: DNTH Ratio Trends

ROIC dramatically improved from -56.4% in Q4 2025 to -15.5% in Q1 2026, marking the strongest quarterly performance since Q2 2024.

• ROIC surged from -56.4% in Q4 2025 to -15.5% in Q1 2026, a 41pp improvement.

• ROE improved 39pp from -52.2% in Q4 2025 to -13.6% in Q1 2026.

• All return metrics remain deeply negative despite recent quarter improvement trends.

⚠ Return metrics hit multi-quarter lows in Q4 2025 before sharp Q1 2026 recovery.

⚠ Sustainability of Q1 2026 improvement uncertain given volatile quarterly pattern throughout 2025.

Get alerted when DNTH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Dianthus Therapeutics, Inc. /DE/ including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DNTH

FMR LLC
$651.9M7,767,686 sh
BlackRock, Inc.
$266.5M3,175,703 sh
RA CAPITAL MANAGEMENT, L.P.
$219.2M2,611,733 sh
WELLINGTON MANAGEMENT GROUP LLP
$217.8M2,595,783 sh
Fairmount Funds Management LLC
$212.9M2,537,191 sh
Avidity Partners Management LP
$184.7M2,104,184 sh
VANGUARD CAPITAL MANAGEMENT LLC
$170.5M2,031,249 sh
Octagon Capital Advisors LP
$163.4M1,946,667 sh
TCG Crossover Management, LLC
$140.7M1,676,624 sh
CITADEL ADVISORS LLC
$135.2M1,610,483 sh

Fund	Value	Shares
FMR LLC	$651.9M	7,767,686
BlackRock, Inc.	$266.5M	3,175,703
RA CAPITAL MANAGEMENT, L.P.	$219.2M	2,611,733
WELLINGTON MANAGEMENT GROUP LLP	$217.8M	2,595,783
Fairmount Funds Management LLC	$212.9M	2,537,191
Avidity Partners Management LP	$184.7M	2,104,184
VANGUARD CAPITAL MANAGEMENT LLC	$170.5M	2,031,249
Octagon Capital Advisors LP	$163.4M	1,946,667
TCG Crossover Management, LLC	$140.7M	1,676,624
CITADEL ADVISORS LLC	$135.2M	1,610,483

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DNTH on your watchlist

Track score changes the day Dianthus Therapeutics, Inc. /DE/ files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DNTH a good stock to buy?

13F Pro's AI-powered analysis of Dianthus Therapeutics, Inc. /DE/ (DNTH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DNTH are available on the DNTH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own DNTH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DNTH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Dianthus Therapeutics, Inc. /DE/'s investment landscape.